0 patents currently held, every record listed here
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
This portfolio holds none of the 7 US patents in force on its record. from the record
Of the 7 now held by other companies, 7 were conveyed to Hoffmann la Roche Inc. in the filing they arrived in. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2018 to 2042.
US 11,389,457
Compound and Method for the Prevention of Transmission of Influenza Virus
Mar 26, 2040
US 12,195,547
Dosing for Combination Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody and ANTI-CD79B Antibody Drug Conjugate
Apr 29, 2042
20232028203320382042
11 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Mar 2034 · High confidence
The most cited patent in this portfolio, cited by 16 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2034.
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
Also notable
Ends Mar 2040 · High confidence
Granted 2022. Computed term ends 2040.
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
Also notable
Ends Apr 2042 · High confidence
Granted 2025. Too new for citation comparison; protection runs to 2042.
conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first.
Also on record: 7 patents in force now held by others · 12 patents ended · 11 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.